111
Participants
Start Date
March 5, 2018
Primary Completion Date
September 9, 2020
Study Completion Date
January 27, 2021
Paclitaxel
Administered by IV infusion
300mg DKN-01
Administered by IV infusion
600mg DKN-01
Administered by IV infusion
University of Virginia Cancer Center, Charlottesville
Florida Cancer Specialists & Research Institute, West Palm Beach
University of Alabama, Birmingham
Tennessee Oncology, PLLC, Nashville
Vanderbilt University Medical Center, Nashville
The University of Tennessee West Cancer Center, Germantown
Ohio State University Wexner Medical Center, Hilliard
Cleveland Clinic, Cleveland
Froedtert and Medical College of Wisconsin, Milwaukee
University of Wisconsin, Madison
University of Chicago, Chicago
HCA Midwest Health System Clinical Research, Kansas City
Stephenson Cancer Center - University of Oklahoma Health Sciences Center, Oklahoma City
University of Texas Southwestern Medical Center, Dallas
HonorHealth, Scottsdale
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Lead Sponsor
Leap Therapeutics, Inc.
INDUSTRY